Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2017 Sep 1:6:e23708.
doi: 10.7554/eLife.23708.

The complex relationship of exposure to new Plasmodium infections and incidence of clinical malaria in Papua New Guinea

Natalie E Hofmann  1   2 , Stephan Karl  3   4 , Rahel Wampfler  1   2 , Benson Kiniboro  4 , Albina Teliki  4 , Jonah Iga  4 , Andreea Waltmann  3   5 , Inoni Betuela  4 , Ingrid Felger  1   2 , Leanne J Robinson #  3   4   5   6 , Ivo Mueller #  3   5   7   8
Affiliations

The complex relationship of exposure to new Plasmodium infections and incidence of clinical malaria in Papua New Guinea

Natalie E Hofmann et al. Elife. .

Abstract

The molecular force of blood-stage infection (molFOB) is a quantitative surrogate metric for malaria transmission at population level and for exposure at individual level. Relationships between molFOB, parasite prevalence and clinical incidence were assessed in a treatment-to-reinfection cohort, where P.vivax (Pv) hypnozoites were eliminated in half the children by primaquine (PQ). Discounting relapses, children acquired equal numbers of new P. falciparum (Pf) and Pv blood-stage infections/year (Pf-molFOB = 0-18, Pv-molFOB = 0-23) resulting in comparable spatial and temporal patterns in incidence and prevalence of infections. Including relapses, Pv-molFOB increased >3 fold (relative to PQ-treated children) showing greater heterogeneity at individual (Pv-molFOB = 0-36) and village levels. Pf- and Pv-molFOB were strongly associated with clinical episode risk. Yearly Pf clinical incidence rate (IR = 0.28) was higher than for Pv (IR = 0.12) despite lower Pf-molFOB. These relationships between molFOB, clinical incidence and parasite prevalence reveal a comparable decline in Pf and Pv transmission that is normally hidden by the high burden of Pv relapses.

Clinical trial registration: ClinicalTrials.gov NCT02143934.

Keywords: p. falciparum; Papua New Guinea; Plasmodium vivax; epidemiology; global health; human; immunity; immunology; malaria; transmission.

PubMed Disclaimer

Conflict of interest statement

No competing interests declared.

Figures

Figure 1.
Figure 1.. P. falciparum and P. vivax molFOB (A), prevalence by qPCR (B) and LM (C) by week of follow-up.
Blue lines, P. falciparum; red lines, P. vivax; solid lines, placebo arm; dashed lines, PQ arm. Open circles in (B) mark enrolment qPCR prevalence for each species.
Figure 1—figure supplement 1.
Figure 1—figure supplement 1.. Definition of new infections for calculating molFOB.
Definition of P. falciparum new infections in two exemplary children is shown. The study design and timelines of follow-up are shown in upper panel: enrolment visit (‘E’), followed by radical treatment (black bar ‘T’) and 235 days of follow-up. The presence of P. falciparum clones by sampling visit is visualized below. Columns represent sampling visits, rows represent P. falciparum msp2 alleles, that is distinct P. falciparum clones. Grey solid circles, P. falciparum negative sample, grey open circle, missing sample due to missed follow-up visit; red circle: sample positive for respective Pf-msp2 allele. New infections were defined as a positive sample preceded by two samples negative for this allele (black rectangles), excluding missed samples (see Child 2, allele F, days 120–200). The time point of new infections is marked by arrows for the two children.
Figure 1—figure supplement 2.
Figure 1—figure supplement 2.. P. ovale and P. malariae prevalence by qPCR during follow-up.
Purple lines, P. ovale; green lines, P. malariae; solid lines, Placebo arm; dashed lines, PQ arm. Open circles mark enrolment qPCR prevalence for each species.
Figure 2.
Figure 2.. Distribution of P.falciparum molFOB (A) and P. vivax molFOB by treatment arm (B).
Relative frequencies among the 466 children are shown.
Figure 3.
Figure 3.. Heterogeneity in molFOB (A, B) and clinical episode risk (C, D) of P.falciparum (A, C) and P. vivax (B, D).
Upper panels show the kriging fit of model predictions of molFOB and clinical episode risk of children in both treatment arms. Lower panels show the standard error relative to the kriging estimate. Dots represent study participants’ houses and are color-coded according to village. Black lines: vehicle-accessible road; dark grey lines: vehicle-inaccessible road; light grey lines: river; red/white cross: health center or aid post; grey square: school or enrolment location. Maps were prepared using ArcGIS 10.2 (Esri, USA).
Figure 4.
Figure 4.. The incidence of P.falciparum (A) and P. vivax (B) clinical episodes relative to molFOB.
Mean clinical episode incidence is shown as bars (left axis) and proportion of clinical episode incidence divided by molFOB as connected dots (right axis). Error bars represent 95% CIs. p-values refer to the differences between groups in the proportion of clinical episodes and new infections, assessed by Chi2 or Fisher’s exact test.
See this image and copyright information in PMC

References

    1. Battle KE, Cameron E, Guerra CA, Golding N, Duda KA, Howes RE, Elyazar IR, Price RN, Baird JK, Reiner RC, Smith DL, Gething PW, Hay SI. Defining the relationship between plasmodium vivax parasite rate and clinical disease. Malaria Journal. 2015;14:191. doi: 10.1186/s12936-015-0706-3. - DOI - PMC - PubMed
    1. Betuela I, Rosanas-Urgell A, Kiniboro B, Stanisic DI, Samol L, de Lazzari E, Del Portillo HA, Siba P, Alonso PL, Bassat Q, Mueller I. Relapses contribute significantly to the risk of plasmodium vivax infection and disease in papua new guinean children 1-5 years of age. The Journal of Infectious Diseases. 2012;206:1771–1780. doi: 10.1093/infdis/jis580. - DOI - PubMed
    1. Bousema T, Griffin JT, Sauerwein RW, Smith DL, Churcher TS, Takken W, Ghani A, Drakeley C, Gosling R. Hitting hotspots: spatial targeting of malaria for control and elimination. PLoS Medicine. 2012;9:e1001165. doi: 10.1371/journal.pmed.1001165. - DOI - PMC - PubMed
    1. Bretscher MT, Valsangiacomo F, Owusu-Agyei S, Penny MA, Felger I, Smith T. Detectability of Plasmodium falciparum clones. Malaria Journal. 2010;9:234. doi: 10.1186/1475-2875-9-234. - DOI - PMC - PubMed
    1. Bruce MC, Donnelly CA, Packer M, Lagog M, Gibson N, Narara A, Walliker D, Alpers MP, Day KP. Age- and species-specific duration of infection in asymptomatic malaria infections in Papua New Guinea. Parasitology. 2000;121:247–256. doi: 10.1017/S0031182099006344. - DOI - PubMed

Publication types

Associated data